menu
    • menu

    Company profile for ONL Therapeutics

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions.​Based on its industry-leading expertise in retinal neuroprotection, ONL is developing breakthrough, first-in-class treatments for serious, vision-threatening retinal diseases and conditions. Preclinical in vivo data, along with a growing body of lite...
    ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions.​Based on its industry-leading expertise in retinal neuroprotection, ONL is developing breakthrough, first-in-class treatments for serious, vision-threatening retinal diseases and conditions. Preclinical in vivo data, along with a growing body of literature, support application of the company’s technology platform in retinal detachment, age-related macular degeneration (AMD), glaucoma and non-infectious uveitis, among other chronic retinal diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ONL TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    PO Box 131547 Ann Arbor, MI 48113
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.onltherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/onl-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ONL Therapeutics Publishes Phase 1B Data On Xelafaslatide
    ONL Therapeutics Publishes Phase 1B Data On Xelafaslatide

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202198/0/en/ONL-Therapeutics-Announces-Publication-of-Data-from-Phase-1b-Study-of-Xelafaslatide-an-Investigational-Therapy-for-Geographic-Atrophy-in-Ophthalmology-Science.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    ONL Therapeutics to Present at Eyenovate & Flor Retina-Icoor
    ONL Therapeutics to Present at Eyenovate & Flor Retina-Icoor

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184356/0/en/ONL-Therapeutics-to-Present-at-EYENOVATE-and-the-FLORetina-ICOOR-Congress-2025.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    ONL Therapeutics Starts Global Phase 2 GALAXY Trial of ONL1204
    ONL Therapeutics Starts Global Phase 2 GALAXY Trial of ONL1204

    28 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/28/3175222/0/en/ONL-Therapeutics-Announces-Randomization-of-First-Patient-in-Global-Phase-2-GALAXY-Trial-of-Xelafaslatide-ONL1204-in-Patients-with-Geographic-Atrophy-GA-Associated-with-Dry-AMD.html

    GLOBENEWSWIRE
    28 Oct 2025
    Share Share
    ONL Therapeutics Announces Presentations at Ophthalmology Meetings
    ONL Therapeutics Announces Presentations at Ophthalmology Meetings

    04 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/04/3020123/0/en/ONL-Therapeutics-Announces-Multiple-Presentations-at-Leading-Ophthalmology-Meetings.html

    GLOBENEWSWIRE
    04 Feb 2025
    Share Share
    ONL Therapeutics Appoints Penny Fleck as Chief Development Officer
    ONL Therapeutics Appoints Penny Fleck as Chief Development Officer

    07 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/07/3005245/0/en/ONL-Therapeutics-Appoints-Penny-Fleck-as-Chief-Development-Officer.html

    GLOBENEWSWIRE
    07 Jan 2025
    Share Share
    ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
    ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing

    13 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/13/2945851/0/en/ONL-Therapeutics-Closes-65-Million-in-Oversubscribed-Series-D-Financing.html

    GLOBENEWSWIRE
    13 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search